



Pedro Manuel Sarmiento Rodrigues Póvoa, MD, PhD

Specialty: Internal Medicine and Intensive Care
Institute: Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental
Department: Intensive Care
City: Lisbon
Country: Portugal
Function: Consultant; Head of department; Associate Professor



Key words: biomarkers, sepsis, epidemiology

What else do I want to say?

I am working full time as an intensive care physician for >20 years, currently at the Polyvalent Intensive Care Unit, Hospital de São Francisco Xavier, CHLO, in Lisbon, Portugal.

I finished my medical degree at the Medical School/University of Lisbon, Internal Medicine training in Hospital de Santa Maria - Medical School/University of Lisbon, and Intensive Care training in Hospital Garcia d'Orta, Almada.

I finished my PhD in 2006 in the NOVA Medical School/New University of Lisbon, and since then I am Professor in the Department of Medicine, being responsible for the area of Acute Care Teaching. And I am also Head of the Polyvalent Intensive Care Unit, Hospital de São Francisco Xavier.

I was also deeply involved in the Portuguese Medical Association in the definition of the training program for Intensive care trainees.

I have served as tutor of a large number of trainees from different backgrounds, mainly internal medicine and anesthesiology, at different levels, but also in teaching undergraduate medical students.

My primary research focus is on biomarkers of infection/sepsis and their different potential uses in the clinical decision process at the bedside. I have also interest in other areas related with infection/sepsis namely antibiotics PK/PD, role of steroids, VAP/VAT, severe CAP, exhaled breath analysis, acute brain dysfunction among others. I have participated in several systematic reviews and meta-analysis. Since 2017, I have been appointed as Adjunct Professor in the University of Southern Denmark, Odense, and I am working in the Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, mainly with population-based studies with biomarkers.